No Break For Sanofi: Seals Another Diabetes Deal

Having just secured a deal with Hanmi Pharmaceutical for its long-acting diabetes products, Sanofi has wasted no time in boosting its diabetes franchise again, by entering into an agreement with Lexicon Pharmaceuticals for sotagliflozin.

Having just secured a deal with Hanmi Pharmaceutical for its long-acting diabetes products, Sanofi has wasted no time in boosting its diabetes franchise again, by entering into an agreement with Lexicon Pharmaceuticals for sotagliflozin.

Sotagliflozin, an oral dual inhibitor of sodium glucose cotransporters 1 and 2 (SGLT-1 and SGLT-2), is being studied in two...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Alimentary/Metabolic

More from Therapeutic Category